ASCO20: How does early treatment influence the sequence of the following treatment if the disease progresses?

In this MEDtalk Eric J. Small, MD and principal investigator of the SPARTAN study, explains the clinical benefits from early treatment of patients with nonmetastatic castration-resistant prostate cancer